All News

Raludotatug deruxtecan demonstrates antitumor activity and manageable safety in platinum-resistant ovarian cancer.

The case shows how such cardiac involvement can mimic neurologic disease and demand complex, multidisciplinary management.

As open enrollment begins November 1, 2025, millions are signing up under enhanced subsidies that are set to expire at the end of this year.

Despite social media frenzy, there is limited evidence around testosterone’s impact on muscle, mood, and other menopausal symptoms.

Experts discuss personalized myasthenia gravis treatment, emphasizing patient education and engagement for optimal care and advocacy in managing this variable disease.

Individuals with both low incomes and health problems were more likely to gain employment when covered by Medicaid.

Bariatric surgery halves mortality and reduces liver, heart, and kidney complications in steatotic liver disease vs nonsurgical care.

Nerandomilast slowed disease progression at 2 doses compared with placebo among US participants in the trial.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Despite improved selectivity, real-world data point to persistent cardiovascular challenges even with next-generation BTKi therapies.

An IPF-derived biomarker profile shows a reproducible association with ILD risk across three RA cohorts.

A recent study reveals a heightened stroke risk in asthma patients recovering from severe COVID-19, emphasizing the need for proactive monitoring and management.

There is a significant link between chronic spontaneous urticaria and cardiovascular disease risk, highlighting the need for routine assessments.

A new population pharmacokinetic and exposure-response analyses shows no added efficacy or safety benefit from higher doses of serplulimab.

Measles vaccinations and preparation can prevent significant strain on financial and public health systems in the country.

Children and adults should watch where they are walking and avoid any thrown objects when participating in Halloween festivities to protect their eyes.

Innovative payer approaches and holistic support could help expand GLP-1 use and improve obesity care outcomes, experts claimed.

Comparable overall survival and distant recurrence outcomes make stereotactic body radiation a feasible alternative.

Rocatinlimab shows real-world promise for moderate to severe AD, enhancing treatment efficacy and reducing steroid reliance, explains Emma Guttman-Yassky, MD, PhD.

Hair loss disorder can lead to a significant psychological and emotional burden that warrants more attention, new research suggests.

Aggressive lifestyle and risk factor control after ablation significantly lowers atrial fibrillation recurrence and improves heart health.

PBM legislation is rising nationwide, which experts emphasize could increase costs and hinder patient care.

Guideline adherence in treating acute lymphoblastic leukemia (ALL) enhances health care resource utilization, especially for adolescent and young adult patients.

Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also benefit from empagliflozin.

Deuruxolitinib 8 mg BID was found to be the most effective oral JAK inhibitor for severe alopecia areata in a new meta-analysis.

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Combining ELR with CT-based measures predicts olfactory recovery in CRSwNP patients, highlighting eosinophils' role in disease severity and dysfunction.

Geni Tunstall, JD, discusses how pharmacy benefit manager reforms, Medicaid changes, and the MAHA initiative may impact managed care pharmacy operations.

Experts at AMCP Nexus 2025 highlighted how real-world data can improve CAR T-cell therapy access and outcomes.

The FDA announced draft guidance to remove clinical efficacy studies for biosimilars and also issued the position that all biosimilars in the US should be interchangeable.